Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. Martín Gimenez, V. M., García Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

David Suran | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

David Suran — Maribor University Medical Centre

David Suran
Affiliation Maribor University Medical Centre
Country Slovenia
Scopus ID 26650243300
Documents 310
Citations 332
h-index 11
Subject Area Cardiovascular Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-4073-9286

David Suran is a Slovenian clinician-scientist associated with Maribor University Medical Centre whose academic contributions focus on cardiovascular pharmacology, myocardial infarction research, renal complications in cardiovascular disease, and clinical cardiology. His published works demonstrate interdisciplinary engagement in cardiology, nephrology, internal medicine, and evidence-based cardiovascular outcomes research. Through extensive clinical investigations and collaborative medical publications, Suran has contributed to the understanding of myocardial infarction management, acute kidney injury, atrial fibrillation, cardiovascular risk assessment, and translational clinical medicine.[1]

Abstract

This academic article presents a structured overview of the research profile and scholarly contributions of David Suran in the fields of cardiovascular medicine and cardiovascular pharmacology. The article summarizes publication trends, citation indicators, collaborative clinical investigations, and thematic areas of research related to myocardial infarction, atrial fibrillation, acute kidney injury, cardiovascular outcomes, and evidence-based medicine. It further evaluates the suitability of the researcher for recognition under the Best Researcher Award category associated with the International Top Pharmaceutical Awards. The analysis reflects the researcher’s sustained participation in peer-reviewed scientific communication and clinically oriented medical investigations.[2]

Keywords

Cardiovascular Pharmacology, Myocardial Infarction, Acute Kidney Injury, Clinical Cardiology, Cardiovascular Outcomes, Internal Medicine, Atrial Fibrillation, Evidence-Based Medicine, Translational Medicine, Cardiovascular Research

Introduction

Cardiovascular diseases remain among the leading causes of global morbidity and mortality, thereby necessitating continuous scientific advancements in prevention, diagnosis, and therapeutic intervention. Clinical cardiology research plays a significant role in improving patient outcomes through observational studies, pharmacological assessments, and evidence-driven treatment approaches. David Suran has contributed to this research landscape through publications addressing cardiovascular complications, myocardial infarction management, renal impairment in cardiovascular conditions, and clinical predictors associated with adverse cardiovascular outcomes.[3]

His academic and clinical work demonstrates integration between hospital-based medical practice and scholarly research activities. Publications indexed through Scopus and ORCID indicate active participation in collaborative research initiatives involving cardiovascular medicine, nephrology, metabolic disorders, and public health-related cardiovascular investigations.[4]

Research Profile

David Suran is affiliated with Maribor University Medical Centre in Slovenia and serves in academic and clinical capacities associated with cardiology and cardiovascular medicine. ORCID records indicate involvement in internal medicine specialization, cardiovascular medicine specialization, and biomedical technology research training.[5]

The researcher’s Scopus profile records 310 documents, 332 citations, and an h-index of 11, reflecting sustained scholarly activity in cardiovascular medicine and related interdisciplinary areas. His research portfolio demonstrates thematic continuity in myocardial infarction studies, atrial fibrillation management, renal dysfunction following cardiovascular intervention, and prognostic cardiovascular biomarkers.[1]

  • Clinical specialization in cardiology and cardiovascular medicine
  • Research emphasis on myocardial infarction and cardiovascular complications
  • Peer-reviewed contributions to nephrology and cardiovascular outcomes research
  • Participation in collaborative translational medicine studies
  • Integration of evidence-based medicine within clinical cardiology practice

Research Contributions

A significant portion of Suran’s research has focused on cardiovascular risk assessment and patient outcomes in myocardial infarction populations. Publications investigating lipoprotein(a), acute kidney injury, obesity-related cardiovascular complications, and atrial fibrillation recurrence contribute to contemporary cardiovascular clinical understanding.[6]

Several studies have explored relationships between cardiovascular biomarkers and patient prognosis in acute myocardial infarction. Research addressing anemia, renal deterioration after percutaneous coronary intervention, and inflammatory or metabolic risk factors illustrates the clinical relevance of his investigations in routine medical practice.[3]

Additional investigations involving machine learning applications in medicine and explainable artificial intelligence demonstrate interdisciplinary engagement beyond traditional cardiovascular pharmacology. These contributions indicate evolving participation in digital health analytics and data-driven clinical methodologies.[3]

Publications

David Suran’s publications focus on cardiovascular pharmacology, myocardial infarction outcomes, atrial fibrillation, and renal complications associated with cardiovascular disease. His research includes clinical studies on lipoprotein(a), acute kidney injury, cardiovascular risk prediction, and interventional cardiology methodologies. Several works also examine evidence-based therapeutic approaches and translational medical applications in cardiovascular medicine.[4]

Research Impact

The scholarly contributions of David Suran demonstrate measurable academic engagement through peer-reviewed publications, interdisciplinary collaboration, and citation visibility in cardiovascular medicine. His work contributes to ongoing clinical discussions concerning myocardial infarction prognosis, cardiovascular complications, and evidence-based therapeutic approaches.[3]

Research outputs indexed in Scopus and ORCID further indicate continuity of scientific productivity and participation in internationally accessible medical literature databases. Studies involving cardiovascular risk biomarkers, renal complications, and outcome-based analyses hold practical significance for clinical cardiology and cardiovascular pharmacology research communities.[4]

Award Suitability

The Best Researcher Award recognizes individuals demonstrating sustained academic productivity, research quality, interdisciplinary collaboration, and meaningful scholarly contributions within their respective domains. David Suran’s publication profile, clinical research involvement, and documented scientific outputs indicate alignment with the evaluative expectations associated with international academic recognition programs.[4]

His research contributions to cardiovascular pharmacology and clinical cardiology demonstrate consistency in peer-reviewed dissemination, evidence-oriented investigation, and participation in clinically relevant scientific studies. The integration of cardiovascular outcomes research with practical clinical observations further strengthens the academic significance of his work within pharmaceutical and medical research communities.[4]

Conclusion

David Suran has established a research profile centered on cardiovascular medicine, myocardial infarction outcomes, and translational clinical investigations. His scholarly work reflects contributions to evidence-based cardiovascular research, interdisciplinary medical collaboration, and clinically applicable scientific inquiry. Through publications indexed in internationally recognized databases, Suran continues to contribute to the advancement of cardiovascular pharmacology and related medical sciences. The cumulative body of work supports his recognition within professional academic award frameworks focused on research excellence and clinical impact.[4]

References

  1. Elsevier. (n.d.). Scopus author details: David Suran, Author ID 26650243300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26650243300
  2. ORCID. (n.d.). David Suran ORCID profile and publication summary.https://orcid.org/0000-0002-4073-9286
  3. Suran, D. et al. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality. Diagnostics.https://doi.org/10.3390/diagnostics14232757
  4. Suran, D. et al. (2023). Obesity and Acute Kidney Injury in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine.https://doi.org/10.3390/jcm12237311
  5. ORCID. (n.d.). Professional activities and academic qualifications of David Suran.https://orcid.org/0000-0002-4073-9286
  6. Suran, D. et al. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Frontiers in Public Health.https://doi.org/10.3389/fpubh.2022.923797
  7. Suran, D. et al. (2019). Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention. Cardiorenal Medicine.https://doi.org/10.1159/000492287

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Evgeni Grigorov | Pharmacovigilance | OncologyPharmaOnc Trailblazer Award

Published on by Top Pharmaceutical
After Completing the Registration Process, your Biography will be displayed here.

Register by using your Entry ID: 2636

Register Here